Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT05909488
PHASE2/PHASE3

Role of UC-MSC and CM to Inhibit Vision Loss in Retinitis Pigmentosa Phase I/II

Sponsor: PT. Prodia Stem Cell Indonesia

View on ClinicalTrials.gov

Summary

The study will perform UC-MSCs and CM transplantation. There are two groups with different dosages. The first group will be transplanted with 1.5 million cells, meanwhile, the second group is 5 million cells. Each group consists of 30 subjects. All groups will be transplanted via the peribulbar route. All groups will be observed until six months.

Official title: Role of Umbilical Cord-derived Stem Cell Transplantation and Conditioned Medium to Inhibit Vision Loss in Retinitis Pigmentosa Phase I/II

Key Details

Gender

All

Age Range

18 Years - 65 Years

Study Type

INTERVENTIONAL

Enrollment

30

Start Date

2026-05

Completion Date

2027-09

Last Updated

2026-02-25

Healthy Volunteers

No

Interventions

BIOLOGICAL

1.5 x 10^6 UC-MSC + CM

1.5 million cells of UC-MSC in 2 ml of Conditioned Medium (CM)

BIOLOGICAL

5 x 10^6 UC-MSC + CM

5 million cells of UC-MSC in 2 ml of Conditioned Medium (CM)

Locations (1)

RSUP Dr. Sardjito

Yogyakarta, DI Yogyakarta, Indonesia